Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors

Papers of special note have been highlighted as: ▪ of interest ▪ of considerable interest

Bibliography

• 1  Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol.114(2),97 (2007).
  MedlineGoogle Scholar
• 2  Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med.322(8),494–500 (1990).
  Medline CASGoogle Scholar
• 3  Weil RJ, Lonser RR, DeVroom HL, Wanebo JE, Oldfield EH. Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J. Neurosurg.98(1 Suppl.),95–105 (2003).
  MedlineGoogle Scholar
• 4  Moss JM, Choi CY, Adler JR Jr, Soltys SG, Gibbs IC, Chang SD. Stereotactic radiosurgical treatment of cranial and spinal hemangioblastomas. Neurosurgery65(1),79–85 (2009).
  MedlineGoogle Scholar
• 5  Wohrer A, Waldhor T, Heinzl H et al. The Austrian brain tumour registry: a cooperative way to establish a population-based brain tumour registry. J. Neurooncol.95(3),401–411 (2009).
  MedlineGoogle Scholar
• 6  Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol.22(14),2865–2872 (2004).
  MedlineGoogle Scholar
• 7  Eichler AF, Plotkin SR. Brain metastases. Curr. Treat. Options Neurol. 10(4),308–314 (2008).
  MedlineGoogle Scholar
• 8  Brown M, Schrot R, Bauer K, LeTendre D. Incidence of first primary central nervous system tumors in California, 2001–2005. J. Neurooncol.94(2),263–273 (2009).
  MedlineGoogle Scholar
• 9  Melisko ME, Glantz M, Rugo HS. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat. Clin. Pract. Oncol.6(1),25 (2009).
  Medline CASGoogle Scholar
• 10  Ranjan T, Abrey LE. Current management of metastatic brain disease. Neurotherapeutics6(3),598 (2009).
  Medline CASGoogle Scholar
• 11  Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J. Neurooncol.70(2),217–228 (2004).▪ Provides insight into the molecular pathways involved in glioma cell migration, which could be potential future therapeutic targets.
  MedlineGoogle Scholar
• 12  Laws ER, Parney IF, Huang W et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project. J. Neurosurg.99(3),467–473 (2003).
  MedlineGoogle Scholar
• 13  Bidros DS, Liu JK, Vogelbaum MA. Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol.6(1),117–125 (2010).
  Medline CASGoogle Scholar
• 14  Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Chemotherapeutic wafers for high grade glioma. In: Cochrane Database of Systematic Reviews. John Wiley and Sons, Ltd, NY, USA (2010).
  Google Scholar
• 15  Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev. Neurother.9(10),1519–1527 (2009).
  Medline CASGoogle Scholar
• 16  Brem SS, Bierman PJ, Black P et al. Central nervous system cancers: clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw.6(5),456–504 (2008).
  Medline CASGoogle Scholar
• 17  Anderson E, Grant R, Lewis SC, Whittle IR. Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years? British J. Neurosurg.22(3),339–349 (2008).▪ A meta-analysis of malignant glioma patient outcome data from 44 clinical trials between 1966 and 2004, which draws attention to the fact that there has been relatively little improvement in patient outcomes over the years.
  Medline CASGoogle Scholar
• 18  Muldoon LL, Soussain C, Jahnke K et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol.25(16),2295–2305 (2007).▪▪ Highlights the historical challenge of effective drug delivery into the CNS across blood–brain, blood–tumor, and blood–cerebrospinal fluid barriers, and highlights the need for the development of innovative treatment and drug delivery approaches into CNS solid malignancies.
  Medline CASGoogle Scholar
• 19  Hildebrand J, Gorlia T, Kros JM et al. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European organisation for research and treatment of cancer Phase III study (EORTC study 26882). Eur. J. Cancer44(9),1210–1216 (2008).
  Medline CASGoogle Scholar
• 20  Grundy RG, Wilne SH, Robinson KJ et al. Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. Eur. J. Cancer46(1),120–133 (2010).
  Medline CASGoogle Scholar
• 21  Nicolaides T, Tihan T, Horn B, Biegel J, Prados M, Banerjee A. High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous system. J. Neurooncol.98(1),117–123 (2009).
  MedlineGoogle Scholar
• 22  Van Genugten JAB, Leffers P, Baumert BG, Tjon-A-Fat H, Twijnstra A. Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J. Neurooncol.96(2),249–257 (2010).
  Medline CASGoogle Scholar
• 23  De Witt Hamer PC. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro. Oncol.12(3),304–316 (2010).
  Medline CASGoogle Scholar
• 24  Fangusaro J. Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J. Child Neurol.24(11),1409–1417 (2009).
  MedlineGoogle Scholar
• 25  Von Holst H, Knochenhauer E, Blomgren H et al. Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta Neurochir.104(1–2),13–16 (1990).
  Medline CASGoogle Scholar
• 26  Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol.10(5),459 (2009).
  Medline CASGoogle Scholar
• 27  Levin VA, Landahl HD, Freeman Dove MA. The application of brain capillary permeability coefficient measurements to pathological conditions and the selection of agents which cross the blood brain barrier. J. Pharmacokinet. Biopharm.4(6),499 (1976).
  Medline CASGoogle Scholar
• 28  Sarin H, Kanevsky A, Wu H et al. Effective transvascular delivery of nanoparticles across the blood–brain tumor barrier into malignant glioma cells. J. Transl. Med.6(80) (2008).▪▪ First study to report that the physiologic upper limit of pore size of the VEGF-derived blood capillaries of CNS solid tumors is approximately 12 nm, based on the findings of a large body of experimental data on presented and discussed in context of the importance of particle blood half-life for effective transcapillary drug delivery into individual solid tumor cells.
  MedlineGoogle Scholar
• 29  Sarin H. Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J. Transl. Med.7,77 (2009).▪▪ Preliminary therapeutic efficacy of a prototypical drug-conjugated imageable dendrimer (Gd–G5 doxorubicin dendrimer) in the RG-2 rodent malignant glioma model in vivo, which is a macromolecular therapy in the 7–10 nm size range.
  MedlineGoogle Scholar
• 30  Vick NA, Khandekar JD, Bigner DD. Chemotherapy of brain tumors. The ‘blood–brain barrier’ is not a factor. Arch. Neurol.34(9),523 (1977).
  Medline CASGoogle Scholar
• 31  Maeda H, Matsumoto T, Konno T, Iwai K, Ueda M. Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on SMANCS. J. Protein Chem.3(2),181–193 (1984).
  CASGoogle Scholar
• 32  Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J. Natl Cancer Inst.99(19),1441–1454 (2007).
  Medline CASGoogle Scholar
• 33  Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev.6,559–593 (1987).▪ Initial discussions on the existence of elevated hydrostatic and oncotic pressures of the solid tumor interstitium and relevance to the ineffectiveness of small molecule chemotherapy drug accumulation in solid tumor cells.
  Medline CASGoogle Scholar
• 34  Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc. Res.37(1),77 (1989).
  Medline CASGoogle Scholar
• 35  Casley-Smith JR. The role of the endothelial intercellular junctions in the functioning of the initial lymphatics. Angiologica9(2),106 (1972).
  Medline CASGoogle Scholar
• 36  Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res.60(16),4324–4327 (2000).
  Medline CASGoogle Scholar
• 37  Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res.48(24 Part 1),7022–7032 (1988).
  Medline CASGoogle Scholar
• 38  Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res.64(11),3731–3736 (2004).
  Medline CASGoogle Scholar
• 39  Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res.67(6),2729–2735 (2007).
  Medline CASGoogle Scholar
• 40  Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science307(5706),58–62 (2005).
  Medline CASGoogle Scholar
• 41  Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an antivascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA93(25),14765–14770 (1996).
  Medline CASGoogle Scholar
• 42  Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Prac. Oncol.3(1),24–40 (2006).▪ Patient outcome data from several anti-VEGF therapy clinical trials is collated and discussed.
  Medline CASGoogle Scholar
• 43  Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin^®) as treatment of recurrent glioblastoma multiforme. Oncologist14(11),1131–1138 (2009).
  Medline CASGoogle Scholar
• 44  Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol.27(28),4733–4740 (2009).
  Medline CASGoogle Scholar
• 45  Verhoeff JJC, Lavini C, van Linde ME et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann. Oncol. doi: 10.1093/annonc/mdp591(2010) (Epub ahead of print).
  MedlineGoogle Scholar
• 46  Greig NH, Soncrant TT, Shetty HU, Momma S, Smith QR, Rapoport SI. Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother. Pharmacol.26(4),263 (1990).
  Medline CASGoogle Scholar
• 47  Toth K, Vaughan M, Peress N, Slocum H, Rustum Y. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am. J. Pathol.149(3),853–858 (1996).
  Medline CASGoogle Scholar
• 48  Schaich M, Kestel L, Pfirrmann M et al. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann. Oncol.20(1),175–181 (2009).
  Medline CASGoogle Scholar
• 49  Sarkaria JN, Kitange GJ, James CD et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer Res.14(10),2900–2908 (2008).
  Medline CASGoogle Scholar
• 50  Toth K, Vaughan MM, Schwartz G et al. Expression of the MRP and MDRI multidrug resistance gene products in 160 untreated human carcinomas studied by immunohistochemical methods in formalin-paraffin sections. Int. J. Surg. Pathol.6(3),145–154 (1998).
  CASGoogle Scholar
• 51  Szakacs G, Annereau JP, Lababidi S et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell6(2),129–137 (2004).
  Medline CASGoogle Scholar
• 52  Sarin H, Kanevsky AS, Fung SH et al. Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J. Transl. Med.7,33 (2009).▪ Evidence in support of drug blood half-life being the driving force for drug fraction accumulation to therapeutic concentrations in the solid tumor interstitium is presented.
  MedlineGoogle Scholar
• 53  Hurria A, Lichtman SM. Clinical pharmacology of cancer therapies in older adults. Br. J. Cancer98(3),517–522 (2008).
  Medline CASGoogle Scholar
• 54  Jen JF, Cutler DL, Pai SM et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm. Res.17(10),1284–1289 (2000).
  Medline CASGoogle Scholar
• 55  Levin VA, Kabra PA, Freeman-Dove MA. Relationship of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) pharmacokinetics of uptake, distribution, and tissue/plasma partitioning in rat organs and intracerebral tumors. Cancer Chemother. Pharmacol.1(4),233 (1978).
  Medline CASGoogle Scholar
• 56  Levin VA, Kabra P. Effectiveness of the nitrosoureas as a function of their lipid solubility in the chemotherapy of experimental rat brain tumors. Cancer Chemother. Rep.58(6),787 (1974).
  Medline CASGoogle Scholar
• 57  Sarin H. Effective transvascular delivery of chemotherapy into cancer cells with imageable nanoparticles in the 7–10 nanometer size range. In: Current Advances in the Medical Application of Nanotechnology. Slevin M (Ed), eBentham Books (2010) (In Press).
  Google Scholar
• 58  Sarin H, Kanevsky A, Wu H et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J. Transl. Med.7(51) doi: 10.1186/1479-5876-7-51 (2009).▪▪ First study to report that the physiologic upper limit of pore size in the VEGF-derived blood capillaries of both CNS solid tumors and non-CNS peripheral solid tumors is approximately 12 nm, as an extension of previous findings on the upper limit of pore size of CNS solid tumors.
  MedlineGoogle Scholar
• 59  Folkman J, Klagsbrun M. Angiogenic factors. Science235(4787),442–447 (1987).▪▪ Important review article as follow-up to Folkman’s initial observations that VEGF drives the process of solid tumor neo-angiogenic blood capillary microvasculature, which is important for solid tumor growth beyond 1–2 mm3.
  Medline CASGoogle Scholar
• 60  Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res.57(4),765–772 (1997).▪ Important study demonstrating that VEGF induces the formation of diaphragmed fenestrae in the endothelial cells of nonfenestrated blood capillaries such as those of skeletal muscle.
  Medline CASGoogle Scholar
• 61  Roberts WG, Delaat J, Nagane M, Huang S, Cavenee WK, Palade GE. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am. J. Pathol.153(4),1239–1248 (1998).▪▪ Detailed morphometric data on the frequency of endothelial cell fenestration in the blood capillaries of intracranial solid tumors and subcutaneous solid tumors is presented.
  Medline CASGoogle Scholar
• 62  Bayliss LE, Kerridge PMT, Russell DS. The excretion of protein by the mammalian kidney. J. Physiol.77(4),386–398 (1933).
  Medline CASGoogle Scholar
• 63  Vorbrodt AW. Ultracytochemical characterization of anionic sites in the wall of brain capillaries. J. Neurocytol.18(3),359–368 (1989).
  Medline CASGoogle Scholar
• 64  Schmidley JW, Wissig SL. Anionic sites on the luminal surface of fenestrated and continuous capillaries of the CNS. Brain Res.363(2),265–271 (1986).
  Medline CASGoogle Scholar
• 65  Brightman MW. Morphology of blood-brain interfaces. Exp. Eye Res.25(Suppl),1–25 (1977).
  MedlineGoogle Scholar
• 66  Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol.40(3),648–677 (1969).
  Medline CASGoogle Scholar
• 67  Vick NA, Bigner DD. Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood–brain barrier function. J. Neurol. Sci.17,29–39 (1972).
  Medline CASGoogle Scholar
• 68  Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J. Angiogenes. Res. (2010) (In Press).
  MedlineGoogle Scholar
• 69  Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflugers Arch.440(5),653–666 (2000).
  Medline CASGoogle Scholar
• 70  Vink H, Duling BR. Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ. Res.79(3),581–589 (1996).
  Medline CASGoogle Scholar
• 71  Squire JM, Chew M, Nneji G, Neal C, Barry J, Michel C. Quasi-periodic substructure in the microvessel endothelial glycocalyx: a possible explanation for molecular filtering? J. Struct. Biol.136(3),239–255 (2001).▪ Arrangement and spacing of the fibers of endothelial glycocalyx layer is modeled on the basis of high-resolution atomic force microscopic visualization of the layer.
  Medline CASGoogle Scholar
• 72  Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res.60(16),4440–4445 (2000).
  Medline CASGoogle Scholar
• 73  Gabizon A, Chisin R, Amselem S et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer64(6),1125–1132 (1991).
  Medline CASGoogle Scholar
• 74  Triguero D, Buciak JB, Yang J, Pardridge WM. Blood–brain barrier transport of cationized immunoglobulin G: enhanced delivery compared with native protein. Proc. Natl Acad. Sci. USA86(12),4761–4765 (1989).
  Medline CASGoogle Scholar
• 75  Weinbaum S, Zhang X, Han Y, Vink H, Cowin SC. Mechanotransduction and flow across the endothelial glycocalyx. Proc. Natl Acad. Sci. USA100,7988–7995 (2003).▪ Comprehensive review on the structure and biology of the endothelial glycocalyx layer of blood capillary walls.
  Medline CASGoogle Scholar
• 76  Fenstermacher JD, Johnson JA. Filtration and reflection coefficients of the rabbit blood–brain barrier. Am. J. Physiol.211(2),341–346 (1966).
  Medline CASGoogle Scholar
• 77  Sorensen SC. The permeability to small ions of tight junctions between cerebral endothelial cells. Brain Res.70(1),174–178 (1974).
  Medline CASGoogle Scholar
• 78  Jain R, Ellika SK, Scarpace L et al. Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade. Am. J. Neuroradiol.29(4),694–700 (2008).
  Medline CASGoogle Scholar
• 79  Ludemann L, Grieger W, Wurm R, Wust P, Zimmer C. Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI. Magn. Reson. Imaging23(8),833 (2005).
  MedlineGoogle Scholar
• 80  Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. Am. J. Roentgenol.178(3),711 (2002).
  MedlineGoogle Scholar
• 81  Leblond CP, Inoue S. Structure, composition, and assembly of basement membrane. Am. J. Anat.185(4),367–390 (1989).
  Medline CASGoogle Scholar
• 82  Charonis AS, Wissig SL. Anionic sites in basement membranes. Differences in their electrostatic properties in continuous and fenestrated capillaries. Microvasc. Res.25(3),265–285 (1983).
  Medline CASGoogle Scholar
• 83  Terayama N, Terada T, Nakanuma Y. An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue. Histopathology29(1),37–43 (1996).
  Medline CASGoogle Scholar
• 84  Carlson EC, Audette JL, Veitenheimer NJ, Risan JA, Laturnus DI, Epstein PN. Ultrastructural morphometry of capillary basement membrane thickness in normal and transgenic diabetic mice. Anat. Rec. A Discov. Mol. Cell Evol. Biol.271A(2),332–341 (2003).
  Google Scholar
• 85  Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol.163(5),1801–1815 (2003).
  MedlineGoogle Scholar
• 86  Ludatscher RM, Gellei B, Barzilai D. Ultrastructural observations on the capillaries of human thyroid tumours. J.Pathol.128(2),57–62 (1979).
  Medline CASGoogle Scholar
• 87  Muldoon LL, Pagel MA, Kroll RA, Roman-Goldstein S, Jones RS, Neuwelt EA. A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery. Am. J. Neuroradiol.20(2),217–222 (1999).
  Medline CASGoogle Scholar
• 88  Shibata S. Ultrastructure of capillary walls in human brain tumors. Acta Neuropathol.78(6),561–571 (1989).
  Medline CASGoogle Scholar
• 89  Wilson CB, Gutin P, Boldrey EB. Single agent chemotherapy of brain tumors. A five year review. Arch. Neurol.33(1),739–744 (1976).
  Medline CASGoogle Scholar
• 90  Young CW, Burchenal JH. Cancer chemotherapy. Annu. Rev. Pharmacol.11,369–386 (1971).
  Medline CASGoogle Scholar
• 91  Fewer D, Wilson CB, Boldrey EB, Enot KJ, Powell MR. The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine. JAMA222(5),549–552 (1972).
  Medline CASGoogle Scholar
• 92  Tentori L, Graziani G. Recent approaches to improve the anti-tumor efficacy of temozolomide. Curr. Med. Chem.16(2),245–257 (2009).
  Medline CASGoogle Scholar
• 93  Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr. Opin. Genet. Dev.18(1),87–96 (2008).▪ Pros and cons of solid cancer treatment with small molecule inhibitors of the c-MET tyrosine kinase pathway are discussed.
  Medline CASGoogle Scholar
• 94  Schor NF. Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol. Ther.121,253–264 (2009).
  Medline CASGoogle Scholar
• 95  Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem.23(6),682–684 (1980).
  Medline CASGoogle Scholar
• 96  Panassaya S, Guocheng W, Barbara RC, Weidong W, Yongfeng W. Skin delivery potency and anti-tumor activities of temozolomide ester prodrugs. Cancer Lett.244(1),42–52 (2006).
  MedlineGoogle Scholar
• 97  Pappenheimer JR. Passage of molecules through capillary walls. Physiol. Rev.33(3),387–423 (1953).▪ Initial experimental and theoretical work that led to the formulation of the classic pore theory of microvascular permeability is presented.
  Medline CASGoogle Scholar
• 98  Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat. Rev.23(1),35–61 (1997).
  Medline CASGoogle Scholar
• 99  Speth PAJ, Van Hoesel QGCM, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet.15(1),15–31 (1988).
  Medline CASGoogle Scholar
• 100  Karnovsky MJ. The ultrastructural basis of capillary permeability studied with peroxidase as a tracer. J. Cell Biol.35(1),213–236 (1967).
  Medline CASGoogle Scholar
• 101  Gill P, Litzow M, Buckner J et al. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Cancer112(8),1805–1811 (2008).
  Medline CASGoogle Scholar
• 102  Dunkel IJ, Finlay JL. High-dose chemotherapy with autologous stem cell rescue for brain tumors. Crit. Rev. Oncol. Hematol.41(2),197–204 (2002).
  MedlineGoogle Scholar
• 103  Dunkel IJ, Gardner SL, Garvin JH Jr, Goldman S, Shibata S. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. J. Clin. Oncol.12(3),297–303 (2010).
  CASGoogle Scholar
• 104  Clarke JL, Iwamoto FM, Sul J et al. Randomized Phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J. Clin. Oncol.27(23),3861–3867 (2009).
  Medline CASGoogle Scholar
• 105  Newton HB. Intra-arterial chemotherapy of primary brain tumors. Curr. Treat. Options Oncol.6(6),519–530 (2005).
  MedlineGoogle Scholar
• 106  Warren K, Gervais A, Aikin A, Egorin M, Balis FM. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Cancer Chemother. Pharmacol.54(3),206–212 (2004).
  Medline CASGoogle Scholar
• 107  Thomas HD, Lind MJ, Ford J, Bleehen N, Calvert AH, Boddy AV. Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. Cancer Chemother. Pharmacol.45(4),284 (2000).
  Medline CASGoogle Scholar
• 108  Decleves X, Amiel A, Delattre JY, Scherrmann JM. Role of ABC transporters in the chemoresistance of human gliomas. Curr. Cancer Drug Targets6(5),433 (2006).
  Medline CASGoogle Scholar
• 109  Moore A, Marecos E, Bogdanov A, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology214,568–574 (2000).
  Medline CASGoogle Scholar
• 110  Rapoport SI. Osmotic opening of the blood–brain barrier: principles, mechanism, and therapeutic applications. Cell. Mol. Neurobiol.20(2),217 (2000).
  Medline CASGoogle Scholar
• 111  Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res.61(7),3027–3032 (2001).
  Medline CASGoogle Scholar
• 112  Kobayashi H, Reijnders K, English S et al. Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin. Cancer Res.10(22),7712–7720 (2004).
  Medline CASGoogle Scholar
• 113  Yordanov AT, Kobayashi H, English SJ et al. Gadolinium-labeled dendrimers as biometric nanoprobes to detect vascular permeability. J. Mater. Chem.13(7),1523–1525 (2003).
  CASGoogle Scholar
• 114  Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg.83(6),1029–1037 (1995).
  Medline CASGoogle Scholar
• 115  Sharma US, Sharma A, Chau RI, Straubinger RM. Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm. Res.14(8),992–998 (1997).
  Medline CASGoogle Scholar
• 116  Hau P, Fabel K, Baumgart U et al. Pegylated liposomal doxorubicin – efficacy in patients with recurrent high-grade glioma. Cancer100(6),1199–1207 (2004).
  Medline CASGoogle Scholar
• 117  Fabel K, Dietrich J, Hau P et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer92(7),1936–1942 (2001).
  Medline CASGoogle Scholar
• 118  Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res.42(6),463–478 (2003).
  Medline CASGoogle Scholar
• 119  Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm.354(1–2),56–62 (2008).
  Medline CASGoogle Scholar
• 120  Erickson BJ, Campeau NG, Schreiner SA, Buckner JC, O’Neill BP, O’Fallon JR. Triple-dose contrast/magnetization transfer suppressed imaging of ‘non-enhancing’ brain gliomas. J. Neurooncol.60(1),25–29 (2002).▪ Clinical evidence that the short blood half-life of small-molecule MRI contrast agents such as Magnevist® is the primary reason that small CNS solid tumor foci often do not contrast enhance and are not visible on high-resolution scans.
  MedlineGoogle Scholar
• 121  Pluen A, Boucher Y, Ramanujan S et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs subcutaneous tumors. Proc. Natl Acad. Sci. USA98(8),4628–4633 (2001).
  Medline CASGoogle Scholar
• 122  Koyama Y, Hama Y, Urano Y, Nguyen DM, Choyke PL, Kobayashi H. Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin. Cancer Res.13(10),2936–2945 (2007).
  Medline CASGoogle Scholar
• 123  Adams GP, Schier R, McCall AM et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res.61(12),4750–4755 (2001).
  Medline CASGoogle Scholar
• 124  Lee CC, Gillies ER, Fox ME et al. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl Acad. Sci. USA103(45),16649 (2006).▪ Utility of acid-labile covalent linkages for the conjugation of small molecule drugs to nanoparticles to facilitate timely drug release in the acidic environment of tumor cell endolysosomal compartments is demonstrated.
  Medline CASGoogle Scholar
• 125  Felgner PL, Gadek TR, Holm M et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl Acad. Sci. USA84(21),7413–7417 (1987).
  Medline CASGoogle Scholar
• 126  Herce HD, Garcia AE. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc. Natl Acad. Sci. USA104(52),20805–20810 (2007).
  Medline CASGoogle Scholar
• 127  Herve F, Ghinea N, Scherrmann JM. CNS delivery via adsorptive transcytosis. AAPS J.10(3),455 (2008).
  Medline CASGoogle Scholar
• 128  Sugahara KN, Teesalu T, Karmali PP et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science328(5981),1031–1035 (2010).
  Medline CASGoogle Scholar
• 129  Harrison PM. The structure of apoferritin: molecular size, shape and symmetry from x-ray data. J. Mol. Biol.6(5),404–422 (1963).
  Medline CASGoogle Scholar
• 130  Brightman MW. The distribution within the brain of ferritin injected into cerebrospinal fluid compartments. I. Ependymal distribution. J. Cell Biol.26(1),99–123 (1965).
  Medline CASGoogle Scholar
• 131  Armstrong JK, Wenby RB, Meiselman HJ, Fisher TC. The hydrodynamic radii of macromolecules and their effect on red blood cell aggregation. Biophys. J.87(6),4259–4270 (2004).
  Medline CASGoogle Scholar
• 132  Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br. J. Cancer82(9),1513–1518 (2000).
  Medline CASGoogle Scholar
• 133  Yuan F, Dellian M, Fukumura D et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res.55(17),3752 (1995).
  Medline CASGoogle Scholar
• 134  Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res.54(13),3352–3356 (1994).
  Medline CASGoogle Scholar
• 135  Campbell RB, Fukumura D, Brown EB et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res.62,6831–6836 (2002).
  Medline CASGoogle Scholar
• 136  Hobbs SK, Monsky WL, Yuan F et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA95,4607–4612 (1998).
  Medline CASGoogle Scholar
• 137  Thurston G, McLean JW, Rizen M et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Inv.101(7),1401–1413 (1998).
  Medline CASGoogle Scholar
• 138  MacKay JA, Deen DF, Szoka FC Jr. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res.1035(2),139–153 (2005).
  Medline CASGoogle Scholar
• 139  Kamba T, Tam BYY, Hashizume H et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol.290(2),H560–576 (2006).
  Medline CASGoogle Scholar
• 140  Lutty GA, Hasegawa T, Baba T, Grebe R, Bhutto I, McLeod DS. Development of the human choriocapillaris. Eye1–8 (2010).
  Google Scholar
• 141  Bearer EL, Orci L, Sors P. Endothelial fenestral diaphragms: a quick-freeze, deep-etch study. J. Cell Biol.100(2),418–428 (1985).
  Medline CASGoogle Scholar
• 142  Melamed S, Ben-Sira I, Ben-Shaul Y. Ultrastructure of fenestrations in endothelial choriocapillaries of the rabbit – a freeze-fracturing study. Br. J. Ophthalmol.64(7),537–543 (1980).
  Medline CASGoogle Scholar
• 143  Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res.46(12 I),6387–6392 (1986).
  Medline CASGoogle Scholar
• 144  Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm.71(3),409 (2009).
  Medline CASGoogle Scholar
• 145  Kobayashi A, Oda T, Maeda H. Protein binding of macromolecular anticancer agent SMANCS: characterization of poly(styrene-co-maleic acid) derivatives as an albumin binding ligand. J. Bioact. Compat. Polym.3(4),319–333 (1988).
  CASGoogle Scholar
• 146  Oda T, Maeda H. Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrene–maleic acid copolymer. Cancer Res.47(12),3206–3211 (1987).
  Medline CASGoogle Scholar
• 147  Oda T, Sato F, Maeda H. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH. J. Natl Cancer. Inst.79(6),1205–1211 (1987).
  Medline CASGoogle Scholar
• 148  Wu G, Barth RF, Yang W et al. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconj. Chem.15(1),185–194 (2003).
  Google Scholar
• 149  Mross K, Niemann B, Massing U et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet^®) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother. Pharmacol.54(6),514–524 (2004).
  Medline CASGoogle Scholar
• 150  Hersh EM, O’Day SJ, Ribas A et al. A Phase II clinical trial of nab-Paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer116(1),155–163 (2010).
  Medline CASGoogle Scholar
• 151  Kukowska-Latallo JF, Candido KA, Cao Z et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res.65(12),5317–5324 (2005).
  Medline CASGoogle Scholar
• 152  Padilla De Jesus OL, Ihre HR, Gagne L, Frechet JMJ, Szoka FC. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconj. Chem.13(3),453–461 (2002).
  Medline CASGoogle Scholar
• 153  Tomalia DA, Reyna LA, Svenson S. Dendrimers as multipurpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem. Soc. Trans.35(Pt 1),61–67 (2007).
  Medline CASGoogle Scholar
• 154  Konda SD, Wang S, Brechbiel M, Weiner EC. Biodistribution of a 153Gd-folate dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts. Invest. Radiol.37(4),199–204 (2002).
  Medline CASGoogle Scholar
• 155  Fukushima T, Takeshima H, Kataoka H. Antiglioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res.29(11),4845–4854 (2009).
  Medline CASGoogle Scholar